SLC5A2 and atherosclerosis: Although their impact on the gut microbiota varies and evidence of their anti-inflammatory effects remains inconsistent, SGLT2 inhibitors remain a valuable therapeutic option for managing atherosclerosis and improving cardiovascular health in patients with T2DM, warranting further research to fully elucidate their multifaceted benefits.